Adjuvant Radiotherapy for Gastric Cancer – Review

Surgical excision forms the main treatment of gastric cancer. However, even after surgery, the median survival is limited to 12 to 20 months due to the high frequency of loco regional and/or metastatic recurrences. This led to clinical trials associating surgery with various forms of neoadjuvant or adjuvant treatments to improve tumour control and patient survival. The most common studied modalities are perioperative chemotherapy and adjuvant chemo-radiotherapy and both of these have shown improved survival. The aim of this review is to compile current knowledge about adjuvant radiotherapy in the management of gastric adenocarcinoma and to discuss the various techniques available and its toxicities.